Cassava Sciences falls 85% after Alzheimer's drug flops – Investor's Business Daily

Cassava Sciences falls 85% after Alzheimer's drug flops – Investor's Business Daily

by


  1. Cassava Sciences drops 85% after Alzheimer's drug flopinvestor's business daily
  2. Cassava Sciences' Alzheimer's drug fails to meet primary goal in key study, pharma halts late-stage studyyahoo finance
  3. Cassava Sciences' Alzheimer's treatment did not meet endpoints in study; Share Dive – Updatemarket Watch
  4. Cassava fails Phase 3 Alzheimer's trial, causing second trial to be ended early and stock to crashfierce biotech
  5. Cassava stocks fall as late-stage study of Alzheimer's drug failsInvestopedia

Leave a Comment

“The Untold Story: Yung Miami’s Response to Jimmy Butler’s Advances During an NBA Playoff Game” “Unveiling the Secrets: 15 Astonishing Facts About the PGA Championship”